CD274 and metastatic melanoma: As this study evaluated a targeted agent (i.e., vemurafenib) in patients with BRAF V600E mutations, the OS of patients in this study may not be representative of the OS of general advanced/metastatic melanoma patients who received conventional therapy before the approval of PD-(L)1 therapy.